Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishima, Shunichi, Miyanaga, Akihiko, Saito, Sho, Yuasa, Mizuki, Takahashi, Satoshi, Kashiwada, Takeru, Sugano, Teppei, Noro, Rintaro, Minegishi, Yuji, Terasaki, Yasuhiro, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946498/
https://www.ncbi.nlm.nih.gov/pubmed/32999231
http://dx.doi.org/10.2169/internalmedicine.5435-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946498/
https://www.ncbi.nlm.nih.gov/pubmed/32999231
http://dx.doi.org/10.2169/internalmedicine.5435-20

Ejemplares similares